Abstracts tagged "registries and treatment"

Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Helga Westerlind¹, Mateusz Maciejewski², Thomas Frisell³, Scott Jelinsky⁴, Daniel Ziemek⁵ and Johan Askling¹, ¹Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Systems Immunology, Inflammation & Immunology,, Pfizer, Cambridge, MA, ³Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Inflammation and Immunology, Pfizer Research and Development, Cambridge, MA, ⁵Systems Immunology, Inflammation & Immunology,, Pfizer, Berlin, Germany
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…
Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Kate Murphy⁹, Yukiko Kimura⁶ and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Patient Partner, San Francisco, CA
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…
Abstract Number: 1924 • 2013 ACR/ARHP Annual Meeting
Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data
Chad L. Deal¹, Gregory J. Strnad², Robert A. Overman^3,4 and Boris Bershadsky^2,5, ¹Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH, ²Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵School of Public Health, University of Minnesota, Minneapolis, MN
Background/Purpose: A patient registry is an organized system that collects uniform data to allow evaluation of specific outcomes for a population with a particular disease.…
Abstract Number: 1605 • 2013 ACR/ARHP Annual Meeting
Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry
Jinoos Yazdany¹, Doruk Erkan², Jorge sanchez-Guerrero³, Bevra H. Hahn⁴, Alana B. Levine², Galina Marder⁵, W. Joseph McCune⁶ and Ellen M. Ginzler⁷, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine, North Shore Long Island Health System, Great Neck, NY, ⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Much of the published experience with belimumab in lupus patients has derived from clinical trials. We examined the non-sponsored experience with belimumab in routine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].